Prospects for miR-21 as a Target in the Treatment of Lung Diseases

Author(s): Yan Ding, Yapeng Hou, Yanhong Liu, Xiaoyong Xie, Yong Cui, Hongguang Nie*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

MicroRNA (miRNA/miR) is a class of small evolutionarily conserved non-coding RNA, which can inhibit the target gene expression at the post-transcriptional level and serve as significant roles in cell differentiation, proliferation, migration and apoptosis. Of note, the aberrant miR-21 has been involved in the generation and development of multiple lung diseases, and identified as a candidate of biomarker, therapeutic target, or indicator of prognosis. MiR-21 relieves acute lung injury via depressing the PTEN/Foxo1-TLR4/NF-κB signaling cascade, whereas promotes lung cancer cell growth, metastasis, and chemo/radio-resistance by decreasing the expression of PTEN and PDCD4 and promoting the PI3K/AKT transduction. The purpose of this review is to elucidate the potential mechanisms of miR-21 associated lung diseases, with an emphasis on its dual regulating effects, which will trigger novel paradigms in molecular therapy.

Keywords: MiR-21, acute lung injury, asthma, idiopathic pulmonary fibrosis, lung cancer, PI3K/AKT signal pathway.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 3
Year: 2021
Published on: 12 February, 2021
Page: [415 - 422]
Pages: 8
DOI: 10.2174/1381612826999200820160608
Price: $65

Article Metrics

PDF: 70